ALPMY Astellas Pharma Inc

USD 9.48 0.00 0
Icon

Astellas Pharma Inc (ALPMY) Stock Analysis and Price Targets

COMMON STOCK | Drug Manufacturers - General | OTC
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Slightly Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 9.48

0.00 (0.00)%

USD 17.62B

0.15M

N/A

N/A

Icon

ALPMY

Astellas Pharma Inc (USD)
COMMON STOCK | OTC
USD 9.48
0.00 0
Take a Tour
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Slightly Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 17.62B

N/A

USD 9.48

Astellas Pharma Inc (ALPMY) Stock Forecast

N/A

Based on the Astellas Pharma Inc stock forecast from 0 analysts, the average analyst target price for Astellas Pharma Inc is not available over the next 12 months. Astellas Pharma Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Astellas Pharma Inc is Slightly Bearish, which is based on 4 positive signals and 9 negative signals. At the last closing, Astellas Pharma Inc’s stock price was USD 9.48. Astellas Pharma Inc’s stock price has changed by -2.47% over the past week, +0.11% over the past month and -42.05% over the last year.

No recent analyst target price found for Astellas Pharma Inc
No recent average analyst rating found for Astellas Pharma Inc

Company Overview Astellas Pharma Inc

Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mut...Read More

https://www.astellas.com

2-5-1, Nihonbashi-Honcho, Tokyo, Japan, 103-8411

0

March

USD

USA

Adjusted Closing Price for Astellas Pharma Inc (ALPMY)

Loading...

Unadjusted Closing Price for Astellas Pharma Inc (ALPMY)

Loading...

Share Trading Volume for Astellas Pharma Inc Shares

Loading...

Compare Performance of Astellas Pharma Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for ALPMY

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Astellas Pharma Inc (Sector: Drug Manufacturers - General )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
AZNCF
AstraZeneca PLC 0.00 (0.00%) USD240.18B 37.75 17.74

ETFs Containing ALPMY

Symbol Name ALPMY's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Astellas Pharma Inc (ALPMY) Stock

Stock Target Advisor's fundamental analysis for Astellas Pharma Inc's stock is Slightly Bearish.

Unfortunately we do not have enough data on ALPMY's stock to indicate if its a good dividend stock.

Unfortunately we do not have enough data on ALPMY's stock to indicate what its average analyst target is.

ALPMY stock's Price/Earning ratio is 486.00. Our analysis grades ALPMY stock's Price / Earning ratio at F. This means that ALPMY stock's Price/Earning ratio is above 97% of the stocks in the Drug Manufacturers - General sector in the OTC exchange. Based on this ALPMY may be a overvalued for its sector.

The last closing price of ALPMY's stock was USD 9.48.

The most recent market capitalization for ALPMY is USD 17.62B.

Unfortunately we do not have enough analyst data on ALPMY's stock to indicate whether its price will go up or not.

We can't find any ETFs which contains Astellas Pharma Inc's stock.

As per our most recent records Astellas Pharma Inc has 0 Employees.

Astellas Pharma Inc's registered address is 2-5-1, Nihonbashi-Honcho, Tokyo, Japan, 103-8411. You can get more information about it from Astellas Pharma Inc's website at https://www.astellas.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...